Low-density lipoprotein Videos

  • Video Library

    Therapeutic Management of Dyslipidaemia

    In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

    Prof. Christopher Cannon

    First published: August 1, 2024  

    View

  • Running time: 35 minutes, 49 seconds

     

    00.16 Lp(a) structure and metabolism

    01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

    02.38 Factors influencing Lp(a) level

    03.35 Physiological functions of Lp(a)

    04.12 Atherogenicity of Lp(a)

    04.56 Clinical implication of Lp(a) elevation

    05.25 Genetic variants associated with increased Lp(a) concentrations

    05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

    07.43 Clinical implication of Lp(a) elevation at low LDL-C

    08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

    09.40 Is reducing Lp(a) physiologically safe?

    10.34 Strategies to lower Lp(a) level

    11.57 Future directions in Lp(a) research

    12.37 Summary

    Video Library

    Lp(a):What is it and its role in atherosclerosis

    In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

    Prof. S. Lale Tokgözoğlu

    First published: March 11, 2024  

    View

  • Running time: 3 minutes, 26 seconds

    Video Library

    The SANTORINI Study: Why Are Lipid Control Therapies Not Working?

    In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.

    First published: July 12, 2023  

    View

  • Running time: 18 minutes

    Video Library

    ESC Congress 2022 Highlights – Part One

    Watch part one of the ESC Highlights Video. In this video Prof. Lale Tokgözoğlu summarizes some of the exciting findings that were presented in ESC 2022.

    Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

    First published: November 1, 2022  

    View

  • Running time: 12 minutes

    Video Library

    ESC Congress 2022 Highlights – Peer-to-Peer Discussion – Part Two

    Watch part two of the ESC Highlights Video wherein Prof. Christopher Cannon and Prof. Lale Tokgözoğlu discuss results of some exciting trials highlighting the significance of Lp(a), PCSK9 inhibitors, patient adherence and compliance.

    Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

    First published: November 1, 2022  

    View